The Superior Ability of Human BDCA3+ (CD141+) Dendritic Cells (DCs) to Cross-Present Antigens Derived From Necrotic Lung Cancer Cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Superior Ability of Human BDCA3+ (CD141+) Dendritic Cells (DCs) to Cross-Present Antigens Derived From Necrotic Lung Cancer Cells

Published:2020-06-19 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Gu Fei-fei,Zhang Kai,Ma Li-li,Liu Yang-yang,Li Chang,Hu Yue,Yang Qi-fan,Liang Jin-yan,Zeng Yu-lan,Wang Yan,Liu Li

Funder

National Natural Science Foundation of China

Key Technologies Research and Development Program

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference46 articles.

1. Cancer statistics in China, 2015;Chen;CA Cancer J Clin.,2016

2. Breakthrough of the year 2013. Cancer immunotherapy;Couzin-Frankel;Science.,2013

3. Cancer immunotherapy via dendritic cells;Palucka;Nat Rev Cancer.,2012

4. Dendritic cells as pharmacological tools for cancer immunotherapy;Anguille;Pharmacol Rev.,2015

5. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets;Tel;Blood.,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stealth mRNA nanovaccines to control lymph node trafficking;Journal of Controlled Release;2024-10

2. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors;Journal of Clinical Oncology;2024-09-01

3. Efferocytosis in dendritic cells: an overlooked immunoregulatory process;Frontiers in Immunology;2024-05-21

4. Group XIV C-type lectins: emerging targets in tumor angiogenesis;Angiogenesis;2024-03-12

5. Conventional type 1 dendritic cells (cDC1) in cancer immunity;Biology Direct;2023-11-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3